Cargando…

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo

BACKGROUND: Circulating levels of cancer antigen (CA) 15–3, a tumor marker and regulator of cellular metabolism, were reduced by metformin in a nonrandomized neoadjuvant study. We examined the effects of metformin (vs placebo) on CA 15–3 in participants of MA.32, a phase III randomized trial in earl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goodwin, Pamela J, Dowling, Ryan J O, Ennis, Marguerite, Chen, Bingshu E, Parulekar, Wendy R, Shepherd, Lois E, Gelmon, Karen A, Whelan, Timothy J, Ligibel, Jennifer A, Hershman, Dawn L, Mayer, Ingrid A, Hobday, Timothy J, Rastogi, Priya, Rabaglio-Poretti, Manuela, Lemieux, Julie, Thompson, Alastair M, Rea, Daniel W, Stambolic, Vuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410139/ https://www.ncbi.nlm.nih.gov/pubmed/34485814 http://dx.doi.org/10.1093/jncics/pkab066

Ejemplares similares

Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial
por: Goodwin, Pamela J., et al.
Publicado: (2021)

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Understanding the benefit of metformin use in cancer treatment
por: Dowling, Ryan JO, et al.
Publicado: (2011)

Metformin and Exercise in Cancer: Better Together
por: Stambolic, Vuk, et al.
Publicado: (2019)

The origin of genetic instability in CCTG repeats
por: Lam, Sik Lok, et al.
Publicado: (2011)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
por: Hilton, John, et al.
Publicado: (2022)

The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor–Positive Breast Cancer
por: Lohmann, Ana Elisa, et al.
Publicado: (2022)

Myotonic Dystrophy-2: Unusual Phenotype Due to a Small CCTG-expansion
por: Finsterer, J, et al.
Publicado: (2018)

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial
por: Prica, Anca, et al.
Publicado: (2021)

The competing mini-dumbbell mechanism: new insights into CCTG repeat expansion
por: Guo, Pei, et al.
Publicado: (2016)

Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study
por: Dowling, Ryan JO, et al.
Publicado: (2015)

Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer
por: Lohmann, Ana Elisa, et al.
Publicado: (2018)

Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
por: Shepshelovich, Daniel, et al.
Publicado: (2018)

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
por: Renouf, Daniel J., et al.
Publicado: (2022)

Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study
por: Elliott, Mitchell J., et al.
Publicado: (2020)

Nek family of kinases in cell cycle, checkpoint control and cancer
por: Moniz, Larissa, et al.
Publicado: (2011)

Massive contractions of Myotonic Dystrophy Type 2-associated CCTG tetranucleotide repeats occur via double strand break repair with distinct requirements for helicases
por: Papp, David, et al.
Publicado: (2023)

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
por: Zhang, Jiahui, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results
por: Kennecke, Hagen F., et al.
Publicado: (2023)

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations
por: Dowling, Ryan J O, et al.
Publicado: (2019)

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions
por: Dowling, Ryan J O, et al.
Publicado: (2019)

Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial
por: Song, Andrew J, et al.
Publicado: (2021)

Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial
por: Song, Andrew J, et al.
Publicado: (2022)

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
por: Eigl, Bernhard Josef, et al.
Publicado: (2018)

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
por: Bartlett, J M S, et al.
Publicado: (2015)

The Unstable CCTG Repeat Responsible for Myotonic Dystrophy Type 2 Originates from an AluSx Element Insertion into an Early Primate Genome
por: Kurosaki, Tatsuaki, et al.
Publicado: (2012)

Treatment of Neuroendocrine Tumor Liver Metastases
por: Lewis, Mark A., et al.
Publicado: (2012)

Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort
por: Chapman, Judith-Anne W, et al.
Publicado: (2013)

A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial
por: Spears, Melanie, et al.
Publicado: (2016)

The Rho Guanine Nucleotide Exchange Factor DRhoGEF2 Is a Genetic Modifier of the PI3K Pathway in Drosophila
por: Chang, Ying-Ju, et al.
Publicado: (2016)

Correction: The Rho Guanine Nucleotide Exchange Factor DRhoGEF2 Is a Genetic Modifier of the PI3K Pathway in Drosophila
por: Chang, Ying-Ju, et al.
Publicado: (2021)

Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial
por: Legrand, Théo, et al.
Publicado: (2022)

Rapid topographic growth of the Taiwan orogen since ~1.3–1.5 Ma
por: Chang, Queenie, et al.
Publicado: (2023)

Manipulating multiple sequence alignments via MaM and WebMaM
por: Alkan, Can, et al.
Publicado: (2005)

Pinning down NuMA
por: Wells, William A.
Publicado: (2001)

Má vlast
por: Heckel, Vilém
Publicado: (1973)

Má vlast
por: Smetana, Bed*rich, 1824-1884
Publicado: (1994)

Má vlast /
por: Smetana, Bed*rich, 1824-1884
Publicado: (1995)

Ma vie
por: Duncan, Isadora, 1877-1927
Publicado: (1943)

Cannot write session to /tmp/vufind_sessions/sess_elk7i9bg222dilfsm568s02pon